Pasar al contenido principal

OPTIMIZACION DE CONTILISANT: DISEÑO, SINTESIS Y EVALUACION BIOLOGICA

PID2019-105813RB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hydrazides as Inhibitors of Histone Deacetylases

  • Carreiras, Maria do Carmo
  • Marco-Contelles, Jose
In this Perspective, we have brought together available biological evidence on hydrazides as histone deacetylase inhibitors (HDACis) and as a distinct type of Zn-binding group (ZBG) to be reviewed for the first time in the literature. N-Alkyl hydrazides have transformed the field, providing innovative and practical chemical tools for selective and effective inhibition of specific histone deacetylase (HDAC) enzymes, in addition to the usual hydroxamic acid and o-aminoanilide ZBG-bearing HDACis. This has enabled efficient targeting of neurodegenerative diseases such as Alzheimer’s disease, cancer, cardiovascular diseases, and protozoal pathologies., JMC thanks AEI (Government of Spain; Grants PID2019-105813RB-C21 and PID2022-136530OB-I00) for support, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contilisant-Belinostat Hybrids: Polyfunctionalized Indole Derivativesas Multineurotarget Drugs for the Potential Treatment ofAlzheimer’s Disease

  • Schäker-Hübner, Linda; T.
  • Toledano-Pinedo, Mireia
  • Eimermacher, Sophia
  • Krasniqi, Vesa
  • Porro-Pérez, Alicia
  • Tan, Kathrin
  • Horn, Gabriele
  • Stegen, Philipp
  • Elsinghorst, Paul W.
  • Wille, Timo
  • Pietsch, Markus
  • Gütschow, Michael
  • Marco-Contelles, José
  • Hansen, Finn K
In this work, we designed, synthesized, and evaluated two types of multineurotargeting compounds using a pharmacophore merging strategy, aiming to develop potential treatments for Alzheimer’s disease. We combined belinostat, an FDA-approved unselective histone deacetylase (HDAC) inhibitor, with the 5-substituted indole core of contilisant, known for its antioxidant and neuroprotective properties as well as its potent inhibitory activity against monoamine oxidases (MAOs), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). Among these, compounds 8c (HDAC1, IC50 = 0.019 μM; HDAC6, IC50 = 0.040 μM; AChE, IC50 = 20.06 μM; BChE, IC50 = 17.10 μM; MAO-B, IC50 = 2.14 μM), and 9c (HDAC1, IC50 = 0.126 μM; HDAC6, IC50 = 0.020 μM; AChE, IC50 = 2.73 μM; BChE, IC50 = 4.03 μM; MAO-B, IC50 = 1.18 μM) emerged as the most promising candidates. These compounds warrant further investigation as potential treatments for Alzheimer’s disease due to their unique inhibition profiles and favorable mode of inhibition., J.M.C. thanks AEI (Government of Spain; Grant PID2019−105813RB-C21) for support. S.E., V.K., and M.P. are gratefulto the Faculty of Applied Natural Sciences, TH Köln −University of Applied Sciences, for financial support. The workof L.S.H., M.G., and F.K.H. is funded by the DeutscheForschungsgemeinschaft (DFG, German Research Founda-tion) − GRK2873 (494832089)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cholinesterase-based inhibitors as multitarget small molecules for the therapy of Alzheimer's disease

  • Marco-Contelles, José
  • Oset-Gasque, M. J.
Herein, we have summarized the most significant results that we have communicated from our laboratories in the last thirty years, highlighting the most potent and attractive ChEIs based hit(lead)-Multitarget Small Molecules, such as (S)-p-methoxytacripyrine (1), ASS234 (2), Contilisant (3), and Contilistat (4), that we have identified in the search for new chemical entities for the therapy of Alzheimer's disease., JMC is very thankful to the large number of collaborators, whose names are mentioned in the text and references, for their effort and hard work. JMC thanks Francisco López-Muñoz (UCJC), and AEI (Grant PID2019-105813RB-C21) for continued support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Generation and validation of a novel multitarget small molecule in glioblastoma

  • Artetxe-Zurutuza, A.
  • Iturrioz-Rodriguez, N.
  • Elizazu, J.
  • Toledano-Pinedo, Mireia
  • Porro-Pérez, A.
  • De Goñi, I.
  • Elua-Pinin, A.
  • Schäker-Hübner, L.
  • Azkargorta, M.
  • Elortza, F.
  • Lòpez-Muñoz, F.
  • Moncho-Amor, Verónica
  • Hansen, F. K.
  • Sampron, N.
  • Marco-Contelles, José
  • Matheu, A.
The development of multitarget small molecules (MSMs) has emerged as a powerful strategy for the treatment of multifactorial diseases such as cancer. Glioblastoma is the most prevalent and malignant primary brain tumor in adults, which is characterized by poor prognosis and a high heterogeneity. Current standards of treatment present limited effectiveness, as patients develop therapy resistance and recur. In this work, we synthesized and characterized a novel multi-target molecule (named DDI199 or contilistat), which is a polyfunctionalized indole derivative developed by juxtaposing selected pharmacophoric moieties of the parent compounds Contilisant and Vorinostat (SAHA) to act as multifunctional ligands that inhibit histone deacetylases (HDACs), monoamine oxidases (MAOs) and cholinesterases (ChEs), and modulate histamine H3 (H3R) and Sigma 1 Receptor (S1R) receptors. DDI199 exerts high cytotoxic activity in conventional glioblastoma cell lines and patient-derived glioma stem cells in vitro. Importantly, it significantly reduces tumor growth in vivo, both alone and in combination with temozolomide (TMZ). The comparison with SAHA showed higher target specificity and antitumor activity of the new molecule. Transcriptomic and proteomic analyses of patient-derived glioma stem cells revealed a deregulation in cell cycle, DNA remodeling and neurotransmission activity by the treatment with DDI199. In conclusion, our data reveal the efficacy of a novel MSM in glioblastoma pre-clinical setting., A.A-Z received a predoctoral fellowship from the Education Department of the Basque Government (PRE_2020_1_0130). N.I-R is the recipient of a Sara Borrell postdoctoral contract (CD22/00076) and V. M-A by Miguel Servet contract (CP23/ 00111) from Carlos III Institute of Health. LSH wants to gratefully acknowledge experimental support by Philipp Stegen. The authors thank the Neurooncology Committee of the Donostia Hospital and the Animal facility and Pathology Service of Biogipuzkoa Institute for their help. This work was supported by grants from Carlos III Institute of Health and the European Regional Development Fund (PI19/01355, PI22/ 01905, DTS24/00153) and Health Department of the Basque Country (2022333034, 2023333012) to AM, AEI (PID2019-105813RB-C21) and UCJC (MITOPI) (2022) to JMC, and Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) −GRK2873 (494832089) to L.S-H and FK.H.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases

  • Toledano-Pinedo, Mireia
  • Porro-Pérez, Alicia
  • Schäker-Hübner, L.
  • Romero, Fernando
  • Dong, M.
  • Samadi, A.
  • Almendros, Pedro
  • Iriepa, I.
  • Bautista-Aguilera, O. M.
  • Rodríguez-Fernández, M. M.
  • Solana-Manrique, C.
  • Sanchis, I.
  • Mora-Morell, A.
  • Rodríguez, A. C.
  • Sánchez-Pérez, A. M.
  • Knez, D.
  • Gobec, S.
  • Bellver-Sanchis, A.
  • Pérez, B.
  • Dobrydnev, A. V.
  • Artetxe-Zurutuza, A.
  • Matheu, A.
  • Siwek, A.
  • Wolak, M.
  • Satała, G.
  • Bojarski, A. J.
  • Doroz-Płonka, Agata
  • Handzlik, J.
  • Godyń, J.
  • Więckowska, A.
  • Paricio, N.
  • Griñán-Ferré, C.
  • Hansen, F. K.
  • Marco-Contelles, José
Herein, we describe the design, synthesis, and biological evaluation of 15 Contilisant+Tubastatin A hybrids. These ligands are polyfunctionalized indole derivatives developed by juxtaposing selected pharmacophoric moieties of Contilisant and Tubastatin A to act as multifunctional ligands. Compounds 3 and 4 were identified as potent HDAC6 inhibitors (IC = 0.012 μM and 0.035 μM, respectively), so they were further evaluated in Drosophila and human cell models of Parkinson’s disease (PD). Both compounds attenuated PD-like phenotypes, such as motor defects, oxidative stress, and mitochondrial dysfunction in PD model flies. Ligands 3 and 4 were also studied in the transgenic Caenorhabditis elegans CL2006 model of Alzheimer’s disease (AD). Both compounds were nontoxic, did not induce undesirable animal functional changes, inhibited age-related paralysis, and improved cognition in the thrashing assay. These results highlight 3 and 4 as novel multifunctional ligands that improve the features of PD and AD hallmarks in the respective animal models., JMC thanks AEI (Government of Spain; Grant PID2019-105813RB-C21) and UCJC [Grant: “In vivo analysis of new analogues of Contilisant (MITOPI) (2022)”] for support. This work is part of the MINA-CM program (number S2022/BMD-7236), funded by the call for the implementation of programs of R&D activities between research groups of the Community of Madrid in Biomedicine 2022 (Order 1171/2022). MTP thanks MINA- CM program (number S2022/BMD-7236) for a contract. MMRF and AP thank Comunidad de Madrid for a “Investigo” Contract (2022-23). II thanks AEI (Government of Spain; Grant PID2019-105813RB-C22) for support. AS thanks the UAEU for financial support by Strategic Research Program-Zayed Center for Health Sciences (Grant # G00003680) and by the SURE PLUS (grant #: G00003976) (2022). CGF thanks AEI (MINECO-FEDER, Government of Spain; Grant PID2022-139016OA-I00), Generalitat de Catalunya (Grant 2021 SGR 00357), and AGAUR (Grant 2023Llavor005). ABS acknowledges the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) for her FI-SDUR fellowship (2021FISDU 00182). Some strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440). DK and SG thank the Slovenian Research and Innovation Agency (Research Core Funding grant P1-0208, and project J1-3018) for finnancial support. LSH wants to greatfully acknowledge experimental support by Philipp Stegen.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contilistat, a New Multitarget Small Polyfunctionalized Indole Derivative

  • Toledano-Pinedo, Mireia
  • Diez-Iriepa, Daniel
  • Porro-Pérez, Alicia
  • Schäker-Hübner, Linda
  • Hanl, Maria
  • Samadi, Abdelouahid
  • Almendros, Pedro
  • Iriepa, Isabel
  • Rodríguez-Fernández, M. Mercedes
  • Griñán-Ferré, Christian
  • Siwek, Agata
  • Wolak, Małgorzata
  • Satała, Grzegorz
  • Bojarski, Andrzej J.
  • Doroż-Płonka, Agata
  • Handzlik, Jadwiga
  • Godyń, Justyna
  • Knez, Damijan
  • Gobec, Stanislav
  • Więckowska, Anna
  • Hansen, Finn K.
  • Marco-Contelles, José
We describe the design, synthesis, and in vitro biological evaluation of contilistat, a novel polyfunctionalized indole derivative designed as a hybrid of contilisant and vorinostat containing key pharmacophoric groups of both parent ligands., J.M.C. thanks AEI (Government of Spain; Grant PID2019-105813RB- C21) and UCJC [Grant: In vivo analysis of new analogues of contilisant (MITOPI) (2022)] for support. M.M.R.F. and A.P. thank Comunidad de Madrid for an Investigo Contract (2022–23). I.I. thanks AEI (Govern- ment of Spain; Grant PID2019-105813RB-C22) for support. D.D.I. thanks the Spanish Ministry of Science, Innovation, and Universities for a predoctoral FPU grant. A.S. and D.D.I. thank the UAEU for finan- cial support by the Strategic Research Program–Zayed Center for Health Sciences (G00003680) and SURE PLUS grant (G00003976) (2022). The research was partly supported by Jageillonian University (project no. N42/DBS/000331). Financial support from the Slovenian Research and Innovation Agency (Research Core Funding grant P1- 0208) is gratefully acknowledged. This research was also supported by the Ministry of Education, Science, and Sport (MIZŠ) and the Euro- pean Regional Development Fund OP20.05187 RI-SI-EATRIS. L.S.H., M.H., and F.K.H. acknowledge partial funding from the Deutsche For- schungsgemeinschaft [GRK2873 (494832089)].FundingInformati, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-based Therapy of Parkinson’s Disease

  • Toledano-Pinedo, Mireia
  • Porro-Pérez, Alicia
  • Schäker-Hübner, Linda
  • Diez-Iriepa, Daniel
  • Iriepa, Isabel
  • Siwek, Agata
  • Wolak, Małgorzata
  • Satała, Grzegorz
  • Bojarski, Andrzej J.
  • Doroz-Płonka, Agata
  • Handzlik, Jadwiga
  • Godyń, Justyna
  • Dallemagne, Patrick
  • Rochais, Christophe
  • Davis, Audrey
  • Since, Marc
  • Pérez, Belén
  • Bellver-Sanchis, Aina
  • Irisarri, Alba
  • Pallàs, Mercè
  • Solana-Manrique, Cristina
  • López-Muñoz, Francisco
  • Ismaili, Lhassane
  • Griñán-Ferré, Christian
  • Paricio, Nuria
  • K. Hansen, Finn
  • Więckowska, Anna
  • Marco-Contelles, José
This article belongs to the Special Issue 25th Anniversary of IJMS: Updates and Advances in Molecular Pathology, Diagnostics, and Therapeutics, Herein, we have identified the polyfunctionalized 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid derivative MTP150 for the treatment of neurodegenerative diseases owing to its efficacy in reducing protein aggregation, modulating matrix metalloproteinase activity, mitigating neuroinflammation, and enhancing DNA damage repair pathways across in vivo Caenorhabditis elegans models of Alzheimer’s disease, Parkinson’s disease (PD), and Huntington’s disease. Further experiments in an in vivo Drosophila model of PD showed that MTP150 increased motor performance, reduced oxidative stress levels, and restored mitochondrial function in model flies. In addition, MTP150 exhibited neuroprotective effects in PD model cells, thereby supporting its therapeutic potential for this disease., J.M.-C. thanks AEI (Government of Spain; Grant PID2019-105813RB-C21) and Comunidad de Madrid (IND2023/BMD-27036) for support. I.I. thanks AEI (Government of Spain; Grant PID2019-105813RB-C22) for support. A.P.-P. is grateful to Comunidad de Madrid (IND2023/BMD27036) for a fellowship. This work was supported by grants PID2022-139016OA-I00 and PDC2022-133441-I00, funded by MICIU/AEI/10.13039/501100011033 and FEDER, UE, awarded to C.G.-F. and M.P.; Generalitat de Catalunya (2021 SGR 00357) to CGF and MP; and University of Valencia (UVINV-AE-3664989) to NP. This study was co-financed by Secretaria d’Universitats i Recerca de Departament d’Empresa i Coneixement de la Generalitat de Catalunya 2022 (Producte 0092; Llavor 005 and 007; to CGF). The work of L.S.-H. and F.K.H. was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), GRK2873 (494832089)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Crosstalk between NLRP3 Signaling and Histone Deacetylases in Inflammasome-Driven Diseases

  • Tan, Kathrin
  • Rodríguez-Fernández, M. Mercedes
  • Keuler, Tim
  • Hansen, Finn K.
  • Gütschow, Michael
  • Weindl, Günther
  • Marco-Contelles, José
The NLRP3 inflammasome is a validated therapeutic target in inflammatory, metabolic, and neurodegenerative diseases. Epigenetic regulators, particularly histone deacetylases (HDACs), have emerged as key modulators of inflammasome priming and activation. Recent advances in medicinal chemistry have provided new chemical modalities for the mechanistic interrogation and the potential therapeutic modulation of NLRP3 signaling. This Perspective dissects the mechanistic interface between HDAC-dependent epigenetic control and NLRP3 signaling and highlights emerging chemical tools, including isoform-selective inhibitors and targeted protein degraders. We discuss the challenges of isoform selectivity, species-specific differences, and the therapeutic potential of HDAC-based strategies to attenuate aberrant NLRP3 activity while minimizing off-target effects. Understanding this epigenetic-inflammasome crosstalk may provide a framework for translating epigenetic modulation into innovative treatments for inflammasome-driven diseases., The work of F.K.H., M.G., and G.W. is funded by the DFG GRK2873 (494832089). J.M.-C thanks AEI (Government of Spain) for support (Grants PID2019-105813RB-C21, PID2022-136530OB-I00, and RED2022-134511-T). M.M.R.F. thanks Ignacio BenitoGómezforhishelpintheanalysisofthe information retrieved by J.M.-C. The TOC graphic and Figures 3 − ■ 5 were created with Biorender.com., Peer reviewed
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

N-Methyl-N-((1-methyl-5-(3-(piperidin-1-yl)propoxy)-1H-benzo[d] imidazol-2-yl)methyl)prop-2-yn-1-amine (MBA-159), a new multitarget small molecule for the therapy of Alzheimer's disease

  • Bautista Aguilera, Óscar Mauricio|||0000-0002-1327-1681
  • Manik, Aleksandra
  • Diez Iriepa, Daniel|||0000-0002-8575-1246
  • Szałaj , Natalia
  • Marco Contelles, José Luis
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • Martínez Alonso, Borja
  • Guarnizo Herrero, Víctor|||0000-0001-9323-3388
  • Torrado Durán, Guillermo|||0000-0002-8865-2083
As part of a project aimed at the pharmacological optimization of Contilisant, herein we describe molecular modelling studies that led to the identification of MBA-159 as a new polyfunctionalized, multitarget-directed ligand and a promising drug candidate for the treatment of Alzheimer?s disease. We synthesized MBA-159 and conducted comprehensive in vitro and in vivo evaluations. In in vivo studies MBA-159 demonstrated favourable pharmacokinetics, anti-amnesic properties and significantly improved non-spatial memory (contextual and recognition memory) in a mouse model of scopolamine-induced amnesia. Additionally, MBA-159 showed a tendency to increase synaptic plasticity biomarkers and reduce neuroinflammatory trends (assessed by qPCR), as well as cognitive enhancement in a senescence-accelerated prone mouse 8 model., Ministerio de Ciencia e Innovación, Ministerio de Economía, Comercio y Empresa
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases

  • Toledano Pinedo, Mireia
  • Porro Pérez, Alicia
  • Paricio, Nuria
  • Griñan Ferré, Christian
  • Hanssen, Finn
  • Schaker-Hubner, Linda
  • Romero, Fernando
  • Dong, Ming
  • Samadi, Abdelouahid
  • Almendros, Pedro
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • Bautista Aguilera, Óscar Mauricio|||0000-0002-1327-1681
  • Rodríguez Fernández, M. Mercedes
  • Marco Contelles, José Luis
Herein, we describe the design, synthesis, and biological evaluation of 15 Contilisant+Tubastatin A hybrids. These ligands are polyfunctionalized indole derivatives developed by juxtaposing selected pharmacophoric moieties of Contilisant and Tubastatin A to act as multifunctional ligands. Compounds 3 and 4 were identified as potent HDAC6 inhibitors (IC50 = 0.012 mu M and 0.035 mu M, respectively), so they were further evaluated in Drosophila and human cell models of Parkinson's disease (PD). Both compounds attenuated PD-like phenotypes, such as motor defects, oxidative stress, and mitochondrial dysfunction in PD model flies. Ligands 3 and 4 were also studied in the transgenic Caenorhabditis elegans CL2006 model of Alzheimer's disease (AD). Both compounds were nontoxic, did not induce undesirable animal functional changes, inhibited age-related paralysis, and improved cognition in the thrashing assay. These results highlight 3 and 4 as novel multifunctional ligands that improve the features of PD and AD hallmarks in the respective animal models., Ministerio de Ciencia, Innovación y Universidades
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Generation and validation of a novel multitarget small molecule in glioblastoma

  • Artetxe Zurutuza, Aizpea
  • Matheu, Ander
  • Iturrioz Rodríguez, Nerea
  • Elizazu, Joseba
  • Toledano Pinedo, Mireia
  • Porro Pérez, Alicia
  • Goni, Irati de
  • Elua Pinin, Alejandro
  • Schaker-Hubner, Linda
  • Azkargorta, Miquel
  • Elortza, Félix
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • Marco Contelles, José Luis
The development of multitarget small molecules (MSMs) has emerged as a powerful strategy for the treatment of multifactorial diseases such as cancer. Glioblastoma is the most prevalent and malignant primary brain tumor in adults, which is characterized by poor prognosis and a high heterogeneity. Current standards of treatment present limited effectiveness, as patients develop therapy resistance and recur. In this work, we synthesized and characterized a novel multi-target molecule (named DDI199 or contilistat), which is a polyfunctionalized indole derivative developed by juxtaposing selected pharmacophoric moieties of the parent compounds Contilisant and Vorinostat (SAHA) to act as multifunctional ligands that inhibit histone deacetylases (HDACs), monoamine oxidases (MAOs) and cholinesterases (ChEs), and modulate histamine H3 (H3R) and Sigma 1 Receptor (S1R) receptors. DDI199 exerts high cytotoxic activity in conventional glioblastoma cell lines and patient-derived glioma stem cells in vitro. Importantly, it significantly reduces tumor growth in vivo, both alone and in combination with temozolomide (TMZ). The comparison with SAHA showed higher target specificity and antitumor activity of the new molecule. Transcriptomic and proteomic analyses of patient-derived glioma stem cells revealed a deregulation in cell cycle, DNA remodeling and neurotransmission activity by the treatment with DDI199. In conclusion, our data reveal the efficacy of a novel MSM in glioblastoma pre-clinical setting., Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades